RNU6-1 in circulating exosomes differentiates GBM from non-neoplastic brain lesions and PCNSL but not from brain metastases

Abstract

Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Circulating biomarkers may assist in the processes of differential diagnosis and response assessment. GBM cells release extracellular vesicles containing a subset of proteins and nucleic acids. We previously demonstrated that exosomes isolated from the serum of GBM patients had an increased expression of RNU6-1 compared to healthy subjects. In this exploratory study, we investigated the role of this small noncoding RNA as a diagnostic biomarker for GBM versus other brain lesions with some potential radiological similarities.

Document Details

Document Type
Pub Defense Publication
Publication Date
Jan 01, 2020
Source ID
10.1093/noajnl/vdaa010

Entities

People

  • Amaia Agirre
  • Ana Patiño-García
  • Beatriz Zandio
  • Eduardo Martínez-vila
  • Gregorio Petrirena
  • Inés Esparragosa Vázquez
  • Jaime Gállego Pérez-Larraya
  • Jaime Gállego-culleré
  • Jordi Bruna
  • Jorge M Nuñez-córdoba
  • Marc Garcia-Moure
  • Marisol Gonzalez-Huarriz
  • Marta M Alonso
  • Miguel Marigil
  • Montserrat Puigdelloses
  • Naiara Martínez-vélez
  • Ricardo Díez-valle
  • Sonia Tejada-solís

Organizations

  • Carlos III Health Institute
  • Clínica Universidad de Navarra
  • European Research Council
  • Hospital Universitario de Navarra
  • Hospital de Bellvitge
  • United States Department of Defense
  • University of Navarre
  • University of the Basque Country

Tags

Fields of Study

  • Biology
  • Medicine

Readers

  • Oncology
  • Oncology and Biomarker-Based Cancer Detection.

Technology Areas

  • Biotechnology